News

The News section of Health Law Asia provides key updates from the healthcare landscape across China and the wider Asian region.
We share news on industry developments, institutional initiatives, international collaborations, healthcare reforms, and trends affecting the pharmaceutical, medical device, and cosmetics sectors.
A concise and reliable source to stay informed about the economic, legal, and industrial dynamics shaping Asia’s healthcare markets.

Pharma, China

Interpretation of Announcement on 2026 Medical Insurance Drug Catalog Preliminary Review Results

See Details
Pharma, China

Notice on Ensuring the Proper Implementation of Work Related to the Segmented Manufacturing of Biological Products

See Details
Pharma, China

Announcement of the 12th National Centralized Volume-Based Procurement of Pharmaceuticals

See Details
Pharma, China

Guiding Principles for the Development of Appropriate Pharmaceutical Packaging Specifications

See Details
Pharma, China

Guiding Opinions on the Standardized Development of Modern Pharmaceutical Logistics

See Details
Pharma, China

Measures for the Administration of Medical Representatives

See Details
Pharma, China

Model Anti-monopoly Case Ruled by the Supreme People's Court (Huang Ltd. et al.)

See Details
Pharma, China

Notice on Issuing the Compliance Guidelines for the Online Retail Sale of Prescription Drugs

See Details
Pharma, China

Good Clinical Practice for Drug Trials

See Details
Pharma, China

Announcement on Strengthening the Supervision and Administration of Entrusted Drug Manufacturing

See Details
Pharma, China

Administrative Public Interest Litigation Case Regarding the Rectification of Disguised Sales of Prohibited Online Medicines in the Form of False Online Consultations

See Details
Pharma, China

Regulations on Inspection of Exported Drugs and Management of Export Certificates for Pharmaceutical Manufacturers

See Details
Pharma, China

Regulations on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies

See Details
Pharma, China

Implementation Measures for Drug Trial Data Protection

See Details
Medical Devices, China, Pharma

Implementation Opinions on Promoting the Integration of Artificial Intelligence into Drug Regulation

See Details
Medical Devices, Other Countries, Pharma

Singapore and Japan Strenghten Regulatory Cooperation in Health Products

See Details
Pharma, China

Bristol Myers Squibb–Hengrui Global Collaboration Agreement

See Details
Pharma, China

Further Optimizing the Review and Approval of Clinically Urgently Needed Overseas Marketed Drugs

See Details
Pharma, China

Opinions on Improving the Drug Price Formation Mechanism

See Details
China, Pharma

Guiding Opinions on the Standardized Development of Modern Pharmaceutical Logistics

See Details
Pharma, Other Countries

Singapore’s HSA Starts Accepting eCTD Packages for Regulatory Dossier Applications

See Details
Medical Devices, China

CMEF 2026 in Shanghai: A global Hub for Medical Innovation and AI-Driven Healthcare

See Details
Pharma, China

Astrazeneca establishes end to end cell therapy capabilities in Shanghai

See Details
Pharma, China, Medical Devices

China 15th Five-Year Plan and Its Implications for the Healthcare Industry

See Details
Pharma, China

Chinese Commerce Minister Meets Pharma Executives to Promote Foreign Investment

See Details
Pharma, China

Several Measures to Support the High-Quality Development of Innovative Drugs

See Details
Medical Devices, Pharma, China

Rewards for Internal Informants Reporting Issues Concerning the Quality and Safety of Medicinal Products and Medical Devices

See Details
China, Pharma

Further Enhancing Matters Related to the Issuance of the Drug Manufacturing License

See Details
Pharma, China

Import of Commercial-scale Batches of Drugs Already Marketed Abroad and Produced Prior to Approval in China

See Details
Corporate, Pharma, China

Antimonopoly Guidelines for the Pharmaceutical sector

See Details
Pharma, China, Corporate

Guidelines for Pharmaceutical Companies to Prevent Commercial Bribery Risks

See Details